Takeda Pharmaceutical Company Limited (TAK)

18.03 +0.00% (+0.00)

Over 5Y: +32.1%

2026-08-28
12.5 15 17.5
2021 2022 2023 2024 2025 2026

Financials Annual

2021 — Revenue: 3.2T 2021 — Operating Cash Flow: 1T 2021 — Free Cash Flow: 899.7B 2021 — Net Income: 376.2B 2022 — Revenue: 3.6T 2022 — Operating Cash Flow: 1.1T 2022 — Free Cash Flow: 999.9B 2022 — Net Income: 230.2B 2023 — Revenue: 4T 2023 — Operating Cash Flow: 977.2B 2023 — Free Cash Flow: 836.5B 2023 — Net Income: 317B 2024 — Revenue: 4.3T 2024 — Operating Cash Flow: 716.3B 2024 — Free Cash Flow: 540.9B 2024 — Net Income: 144.2B 2025 — Revenue: 4.6T 2025 — Operating Cash Flow: 1.1T 2025 — Free Cash Flow: 856.4B 2025 — Net Income: 108.1B 0 1T 2T 3T 4T 5T
2021 2022 2023 2024 2025
Revenue Operating Cash Flow Free Cash Flow Net Income

Figures as at 2025-03-31, reported in JPY. The newest fact in the filings is dated 2026-03-31, 152 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

4.3
OE margin 17.1%
ROIC 2.3%
Accruals -6.7%
OCF / EBIT 3.1×
FCF margin 18.7%
OCF margin 23.1%
ROA 0.76%
ROCE 2.9%
ROE 1.6%
Gross margin —

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

0.5
RPO / sales —
RPO growth —
Segment HHI —

0 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

1.6
ND/EBITDA —
Debt / Eq 0.73×
Debt payback 5.5 yr
Net debt / Eq 0.68×
Cash / Debt 0.076×
Payout 279.7%
Quick ratio 0.52×
Cash runway —
F-score —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

1.9
Sales/sh Y/Y +5.8%
EPS Y/Y -26.2%
EPS CAGR 4Y -27.2%
Div. growth —
EBIT CAGR —
EBIT Y/Y —
EPS next Y —
Sales CAGR 4Y —
Sales Q/Q —

1 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.